Currently, research on neuroprotective treatments for AD have focused on the amyloid hypothesis, in which abnormal metabolism of APP leads to the formation of toxic Aβ species and subsequent manifestation of the pathological features of AD. This evidence concerns the gene APP and Alzheimer disease.